MSLN and neoplasm: An interesting feature of the mesothelin/CD3 2 + 1 bispecific is that it can increase retention of target antigen on the surface of the cell by controlling endosomal trafficking and, thus, enable T cell engagement and killing of tumor cells [69,70].